VR Logo

Clene Inc. (CLNN) download report


Healthcare | Biotechnology & Pharma Research

Clene Inc. (CLNN) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.

IPO Date: 31-Dec-2020

CEO, Pres & Director: Mr. Robert Etherington MBA

Co-Founder & Chief Science Officer: Mr. Mark G. Mortenson

Listing: NASDAQ: CLNN

Country: United States

Headquarters: Salt Lake City, UT

Website: https://clene.com

Key Facts

Market cap: $153.08 Mln

Revenue (TTM): $0.20 Mln

Earnings (TTM): $16.66 Mln

Cash: $36.52 Mln

Total Debt: $25.82 Mln

Insider's Holding: 68.64%

Liquidity: Low

52 Week range: $1.93 - 17.82

Shares outstanding: 63,256,500

Stock Performance

Time Period Clene (CLNN) S&P BSE Sensex S&P Small-Cap 600
YTD-29.27-9.49-17.79
1 month6.23-2.87-2.72
3 months-1.02-8.59-12.17
1 Year-73.300.81-15.82
3 Years-34.2410.397.14
5 Years--11.116.20
10 Years--12.0010.33
As on 24-Jun-2022
Year Clene (CLNN) S&P Small-Cap 600 S&P BSE Sensex
2021-54.5025.2721.99
2020-13.999.5715.75
20195.8520.8614.38